ImmuPharma plc (AIM:IMM)
London
· Delayed Price · Currency is GBP · Price in GBX 3.010
-0.045 (-1.47%)
Mar 28, 2025, 12:35 PM GMT+1
ImmuPharma Revenue
ImmuPharma had revenue of -69.96K GBP in the twelve months ending June 30, 2024, down -200.00% year-over-year.
Revenue (ttm)
-69.96K
Revenue Growth
-200.00%
P/S Ratio
n/a
Revenue / Employee
-13.99K
Employees
5
Market Cap
12.72M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
ImmuPharma News
- 4 days ago - FX positioning info - Net speculative EUR longs surged in a sharp rise from previous week - Forexlive
- 11 days ago - Data show speculative traders have flipped from a net short to a net long position on euro - Forexlive
- 2 months ago - AIM Market Roundup: Immupharma, Poolbeg, Xeros - The Armchair Trader
- 7 months ago - Three Quick Facts: Norman Broadbent, Computacenter, Immupharma - The Armchair Trader